Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Psoriatic | 8 | 2024 | 219 | 2.300 |
Why?
|
| Psoriasis | 9 | 2024 | 940 | 2.030 |
Why?
|
| Dermatomyositis | 4 | 2024 | 256 | 1.180 |
Why?
|
| Alopecia Areata | 1 | 2022 | 127 | 0.680 |
Why?
|
| Finger Phalanges | 1 | 2019 | 41 | 0.650 |
Why?
|
| Ecosystem | 1 | 2023 | 485 | 0.640 |
Why?
|
| Awards and Prizes | 1 | 2022 | 359 | 0.590 |
Why?
|
| Brain Abscess | 1 | 2017 | 120 | 0.540 |
Why?
|
| Rheumatology | 1 | 2022 | 611 | 0.520 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 716 | 0.460 |
Why?
|
| Gingival Diseases | 1 | 2014 | 36 | 0.450 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 264 | 0.440 |
Why?
|
| Facial Dermatoses | 1 | 2014 | 85 | 0.430 |
Why?
|
| Pemphigoid, Bullous | 1 | 2014 | 114 | 0.400 |
Why?
|
| Dermatology | 1 | 2022 | 914 | 0.390 |
Why?
|
| Radiography | 1 | 2019 | 6965 | 0.310 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2532 | 0.280 |
Why?
|
| Ultrasonography | 1 | 2019 | 5961 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 4024 | 0.220 |
Why?
|
| Raynaud Disease | 1 | 2023 | 79 | 0.220 |
Why?
|
| Connective Tissue Diseases | 1 | 2024 | 286 | 0.190 |
Why?
|
| Antirheumatic Agents | 2 | 2021 | 1374 | 0.190 |
Why?
|
| Dermatologic Agents | 2 | 2024 | 307 | 0.190 |
Why?
|
| Autoimmune Diseases | 3 | 2024 | 2250 | 0.180 |
Why?
|
| Epithelium | 2 | 2024 | 1605 | 0.180 |
Why?
|
| Duodenal Diseases | 1 | 2021 | 99 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2024 | 621 | 0.180 |
Why?
|
| Glycolysis | 1 | 2024 | 828 | 0.170 |
Why?
|
| Enteritis | 1 | 2021 | 162 | 0.170 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2021 | 124 | 0.170 |
Why?
|
| Uremia | 1 | 2019 | 201 | 0.160 |
Why?
|
| Interferons | 1 | 2022 | 705 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 7408 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2021 | 2159 | 0.150 |
Why?
|
| Interleukin-17 | 1 | 2024 | 910 | 0.150 |
Why?
|
| Alopecia | 1 | 2022 | 414 | 0.150 |
Why?
|
| Methotrexate | 1 | 2024 | 1719 | 0.140 |
Why?
|
| Skin | 4 | 2024 | 4466 | 0.140 |
Why?
|
| Arthritis | 1 | 2022 | 666 | 0.140 |
Why?
|
| Biological Products | 3 | 2021 | 916 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 664 | 0.140 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2017 | 96 | 0.140 |
Why?
|
| Microvessels | 1 | 2021 | 572 | 0.140 |
Why?
|
| Pruritus | 1 | 2019 | 377 | 0.130 |
Why?
|
| Pyrroles | 1 | 2022 | 1137 | 0.130 |
Why?
|
| Etoposide | 1 | 2017 | 630 | 0.130 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2024 | 911 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 13262 | 0.120 |
Why?
|
| Neutrophil Infiltration | 1 | 2017 | 393 | 0.120 |
Why?
|
| Cheek | 1 | 2014 | 65 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 12965 | 0.110 |
Why?
|
| Piperidines | 1 | 2022 | 1650 | 0.110 |
Why?
|
| Blindness | 1 | 2017 | 582 | 0.110 |
Why?
|
| Giant Cell Arteritis | 1 | 2017 | 295 | 0.110 |
Why?
|
| Humans | 25 | 2024 | 760621 | 0.110 |
Why?
|
| Craniotomy | 1 | 2017 | 741 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 2234 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 6498 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2017 | 965 | 0.090 |
Why?
|
| Adult | 12 | 2024 | 219994 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2019 | 1801 | 0.090 |
Why?
|
| Nose | 1 | 2014 | 519 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2022 | 3016 | 0.090 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 3022 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2017 | 1927 | 0.080 |
Why?
|
| Prednisone | 1 | 2014 | 1565 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2020 | 3763 | 0.080 |
Why?
|
| Inflammation | 3 | 2024 | 10756 | 0.070 |
Why?
|
| HIV Infections | 1 | 2014 | 17165 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 1796 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 2471 | 0.070 |
Why?
|
| Proteomics | 1 | 2020 | 3817 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 3218 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2014 | 4035 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2022 | 65017 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8552 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 4312 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 11152 | 0.060 |
Why?
|
| Genomics | 1 | 2020 | 5794 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2021 | 11481 | 0.060 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2024 | 186 | 0.060 |
Why?
|
| Male | 10 | 2024 | 359744 | 0.060 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2024 | 144 | 0.050 |
Why?
|
| Disease Progression | 1 | 2020 | 13502 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
| Female | 11 | 2024 | 391270 | 0.050 |
Why?
|
| Biopsy | 1 | 2014 | 6771 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2024 | 713 | 0.050 |
Why?
|
| Middle Aged | 8 | 2024 | 220352 | 0.050 |
Why?
|
| Complement Pathway, Mannose-Binding Lectin | 1 | 2021 | 28 | 0.050 |
Why?
|
| Interleukin-23 | 1 | 2022 | 197 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12626 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11712 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 791 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 15840 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2024 | 1134 | 0.040 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2020 | 152 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 418 | 0.040 |
Why?
|
| Endoscopy, Digestive System | 1 | 2021 | 351 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2021 | 782 | 0.040 |
Why?
|
| New York | 1 | 2020 | 875 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2024 | 787 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1722 | 0.040 |
Why?
|
| Urea | 1 | 2019 | 446 | 0.040 |
Why?
|
| Dizziness | 1 | 2019 | 257 | 0.030 |
Why?
|
| Edema | 1 | 2021 | 769 | 0.030 |
Why?
|
| Necrosis | 1 | 2021 | 1612 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2020 | 547 | 0.030 |
Why?
|
| Risk Factors | 3 | 2024 | 74359 | 0.030 |
Why?
|
| Remission Induction | 1 | 2021 | 2392 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 10344 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2022 | 2118 | 0.030 |
Why?
|
| Incidence | 2 | 2022 | 21392 | 0.030 |
Why?
|
| Ischemia | 1 | 2021 | 1893 | 0.020 |
Why?
|
| Aged | 5 | 2024 | 169152 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2020 | 2145 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3361 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 36290 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2024 | 9287 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2024 | 14372 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2022 | 12427 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2022 | 12766 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 11071 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 20080 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 54303 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2023 | 22053 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 22023 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 2421 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 18137 | 0.020 |
Why?
|
| United States | 2 | 2023 | 72461 | 0.010 |
Why?
|
| Depression | 1 | 2023 | 8044 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2024 | 41335 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2024 | 23376 | 0.010 |
Why?
|
| Hospitalization | 1 | 2020 | 10790 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8624 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20509 | 0.010 |
Why?
|
| Mice | 1 | 2024 | 81208 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 58995 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 58741 | 0.010 |
Why?
|
| Animals | 1 | 2024 | 167963 | 0.010 |
Why?
|
Concepts
(141)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_